TABLE 2.
National Programs, Availability, and Financing of DAAs in Latin American Countries
| Country | Government Financial Coverage | National Clinical Guidelines (Latest Version) | Screening | National Registry Patients Treated | DAAs Available | Generic DAAs |
|---|---|---|---|---|---|---|
| Argentina | Yes | Yes (2020) | Universal | Yes | SOF, LDV, VEL, VOX, EBV/GZR, GLE/PIB | Yes |
| Brazil | Yes | Yes (2019) | Universal | Yes | SOF, LDV, VEL, EBV/GZR, GLE/PIB | Yes |
| Chile | Yes | Yes (2019) | Risk populations | Yes | SOF, LDV, VEL, EBV/GZR | No |
| Colombia | Yes | Yes (2019) | Risk populations | Yes | SOF, LDV, VEL, VOX, EBV/GZR, GLE/PIB | No |
| Dominican Republic | Yes | Yes | Risk populations | No | SOF, LDV, VEL, VOX | No |
| Ecuador | No | No | Risk populations | No | SOF | No |
| Mexico | Yes | Yes (2018) | Risk populations | Yes | SOF, VEL, GLE/PIB | |
| No | ||||||
| Peru | No | Yes (2018) | Risk populations | No | SOF, VEL, EBV/GZR | No |
| Uruguay | No | No | Risk populations | No | SOF, LDV, VEL, GLE/PIB | No |